Atypical hemolytic uremic syndrome

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 15:39, 5 June 2015 by Jwarner (talk | contribs) (Created page with "To be completed ===References=== # Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, e...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

To be completed

References

  1. Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015 May 21;125(21):3253-62. Epub 2015 Apr 1. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Atypical_hemolytic_uremic_syndrome&oldid=8043"